The present invention aims to obtain an optical isomer of DCP-LA, which shows more superior activity and is suitable for clinical utilization, and provide an agent having a superior PKC-ε activation action, a prophylactic and/or therapeutic agent for neurotransmitter release disorders, and a prophylactic and/or therapeutic agent for neuropsychiatric diseases, which contain the isomer as an active ingredient.
A compound represented by the following formula:
or a pharmaceutically acceptable salt thereof, and a selective PKC-ε activator containing same as an active ingredient, and is the like.
本发明旨在获得一种DCP-
LA的光学异构体,其显示更优越的活性并适用于临床利用,并提供一种具有卓越的PKC-ε激活作用的药剂,一种神经递质释放障碍的预防和/或治疗剂以及一种神经精神疾病的预防和/或治疗剂,其中包含该异构体作为活性成分。化合物表示为以下公式:或其药学上可接受的盐,以及含有其作为活性成分的选择性PKC-ε激活剂等。